{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T06:07:39Z","timestamp":1747202859006,"version":"3.40.5"},"reference-count":9,"publisher":"Archives of Endocrinology and Metabolism","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,3,23]]},"DOI":"10.20945\/2359-3997000000451","type":"journal-article","created":{"date-parts":[[2022,3,25]],"date-time":"2022-03-25T12:12:01Z","timestamp":1648210321000},"source":"Crossref","is-referenced-by-count":1,"title":["Peptide receptor radionuclide therapy (PRRT) in radioiodine-refractory thyroid cancer: A case report of significant response to lu177 DOTA-TATE treatment"],"prefix":"10.20945","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7647-2632","authenticated-orcid":false,"given":"Saeideh","family":"Ataei-Nakhaei","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2403-8903","authenticated-orcid":false,"given":"Kamran","family":"Aryana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1676-8615","authenticated-orcid":false,"given":"Sayyed Mostafa","family":"Mostafavi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4693-2183","authenticated-orcid":false,"given":"Hadis Mohammadzadeh","family":"Kosari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8582-5658","authenticated-orcid":false,"given":"Mohammad","family":"Esmatinia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1351-3142","authenticated-orcid":false,"given":"Atena","family":"Aghaee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"8510","reference":[{"issue":"1","key":"key20220325081106_B1","first-page":"39","article-title":"Peptide receptor radionuclide therapy of treatment-refractory metastatic thyroid cancer using (90)Yttrium and (177)Lutetium labeled somatostatin analogs: toxicity, response and survival analysis","volume":"4","author":"Budiawan","year":"2014","unstructured":"1 Budiawan H, Salavati A, Kulkarni HR, Baum RP. Peptide receptor radionuclide therapy of treatment-refractory metastatic thyroid cancer using (90)Yttrium and (177)Lutetium labeled somatostatin analogs: toxicity, response and survival analysis. Am J Nucl Med Mol Imaging. 2014;4(1):39-52.","journal-title":"Am J Nucl Med Mol Imaging"},{"issue":"5","key":"key20220325081106_B2","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/S2213-8587(13)70215-8","article-title":"Definition and management of radioactive iodine-refractory differentiated thyroid cancer","volume":"2","author":"Schlumberger","year":"2014","unstructured":"2 Schlumberger M, Brose M, Elisei R, Leboulleux S, Luster M, Pitoia F, et al. Definition and management of radioactive iodine-refractory differentiated thyroid cancer. Lancet Diabetes Endocrinol. 2014;2(5):356-8.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9","key":"key20220325081106_B3","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1038\/modpathol.2010.117","article-title":"Poorly differentiated carcinoma of the thyroid: validation of the Turin proposal and analysis of IMP3 expression","volume":"23","author":"Asioli","year":"2010","unstructured":"3 Asioli S, Erickson LA, Righi A, Jin L, Volante M, Jenkins S, et al. Poorly differentiated carcinoma of the thyroid: validation of the Turin proposal and analysis of IMP3 expression. Mod Pathol. 2010;23(9):1269-78.","journal-title":"Mod Pathol"},{"key":"key20220325081106_B4","doi-asserted-by":"crossref","first-page":"bcr2015213627","DOI":"10.1136\/bcr-2015-213627","article-title":"Lu-177 labelled peptide treatment for radioiodine refractory differentiated thyroid carcinoma","volume":"2016","author":"Elbo\u011fa","year":"2016","unstructured":"4 Elbo\u011fa U, \u00d6zkaya M, Sayiner ZA, \u00c7elen YZ. Lu-177 labelled peptide treatment for radioiodine refractory differentiated thyroid carcinoma. BMJ Case Rep. 2016;2016:bcr2015213627.","journal-title":"BMJ Case Rep"},{"issue":"2","key":"key20220325081106_B5","first-page":"116","article-title":"Use of (177)Lu-dotatate in the treatment of iodine refractory thyroid carcinomas","volume":"36","author":"Oliv\u00e1n-Sasot","year":"2017","unstructured":"5 Oliv\u00e1n-Sasot P, Falg\u00e1s-Lacueva M, Garc\u00eda-S\u00e1nchez J, Vera-Pinto V, Olivas-Arroyo C, Bello-Arques P. Use of (177)Lu-dotatate in the treatment of iodine refractory thyroid carcinomas. Rev Esp Med Nucl Imagen Mol. 2017;36(2):116-9.","journal-title":"Rev Esp Med Nucl Imagen Mol"},{"issue":"10","key":"key20220325081106_B6","doi-asserted-by":"crossref","first-page":"e346","DOI":"10.1097\/RLU.0000000000002219","article-title":"177Lu-DOTATATE therapy in radioiodine-refractory differentiated thyroid cancer: a single center experience","volume":"43","author":"Roll","year":"2018","unstructured":"6 Roll W, Riemann B, Sch\u00e4fers M, Stegger L, Vrachimis A. 177Lu-DOTATATE therapy in radioiodine-refractory differentiated thyroid cancer: a single center experience. Clin Nucl Med. 2018;43(10):e346-e51.","journal-title":"Clin Nucl Med"},{"issue":"2","key":"key20220325081106_B7","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s00005-014-0318-6","article-title":"Peptide receptor radionuclide therapy of differentiated thyroid cancer: efficacy and toxicity","volume":"63","author":"Czepczy\u0144ski","year":"2015","unstructured":"7 Czepczy\u0144ski R, Matysiak-Grze\u015b M, Gryczy\u0144ska M, B\u0105czyk M, Wyszomirska A, Stajgis M, et al. Peptide receptor radionuclide therapy of differentiated thyroid cancer: efficacy and toxicity. Arch Immunol Ther Exp (Warsz). 2015;63(2):147-54.","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"key":"key20220325081106_B8","first-page":"111","article-title":"An alternative therapy option in metastatic thyroid Cancer: peptide receptor radionuclide therapy","author":"\u00c7inkir","year":"2020","unstructured":"8 \u00c7inkir HY, Elbo\u011fa U. An alternative therapy option in metastatic thyroid Cancer: peptide receptor radionuclide therapy. \u0130stanbul T\u0131p Fak\u00fcltesi Dergisi. 2020:111-20.","journal-title":"\u0130stanbul T\u0131p Fak\u00fcltesi Dergisi"},{"issue":"4","key":"key20220325081106_B9","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1089\/thy.2013.0225","article-title":"Differentiated thyroid cancer: a new perspective with radiolabeled somatostatin analogues for imaging and treatment of patients","volume":"24","author":"Versari","year":"2014","unstructured":"9 Versari A, Sollini M, Frasoldati A, Fraternali A, Filice A, Froio A, et al. Differentiated thyroid cancer: a new perspective with radiolabeled somatostatin analogues for imaging and treatment of patients. Thyroid. 2014;24(4):715-26.","journal-title":"Thyroid"}],"container-title":["Archives of Endocrinology and Metabolism"],"original-title":[],"language":"en","deposited":{"date-parts":[[2022,3,25]],"date-time":"2022-03-25T12:12:12Z","timestamp":1648210332000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aem-sbem.com\/article\/peptide-receptor-radionuclide-therapy-prrt-in-radioiodine-refractory-thyroid-cancer-a-case-report-of-significant-response-to-lu177-dota-tate-treatment\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,23]]},"references-count":9,"alternative-id":["10.20945\/2359-3997000000451"],"URL":"https:\/\/doi.org\/10.20945\/2359-3997000000451","relation":{},"ISSN":["2359-3997","2359-4292"],"issn-type":[{"type":"print","value":"2359-3997"},{"type":"electronic","value":"2359-4292"}],"subject":[],"published":{"date-parts":[[2022,3,23]]}}}